

In the name of God



Department of Internal Medicine

Shiraz E-Medical Journal

Vol. 7, No. 1, January 2006

Preliminary Report of Interferon α 2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study.

Alavian SM*, Kabir A**, Hajarizadeh B \pm , Nayebpour M \ddagger , Dorodi T \pm , Baralle FE $\pm\pm$.

* Associate professor; Department Medicine, Section of Gastroenterology, Baghiatollah University of Medical Sciences; Dean of Tehran Hepatitis Center, Tehran, Iran; ** Methodology and statistics consultant; Tehran Hepatitis Center, Tehran, Iran; \pm Research Fellow, Tehran Hepatitis Center, Tehran, Iran; \ddagger Assistant professor of pharmacology, Faculty of pharmacy, Tehran University of Medical Sciences, Tehran, Iran; $\pm\pm$ Professor and Director of International Center for Genetic Engineering and Biotechnology, Trieste, Italy.

Correspondence: Dr. Seyed-Moayed Alavian, No. 92, Vesal Shirazi Ave, P.O.Box 14155/3651, Tehran, Iran, Email: manager@iranhepgroup.info.

Abstract:

Aim: The addition of ribavirin (RIBA) to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monotherapy to 40-45% in combination therapy. The aim of this study is to assess the therapeutic efficacy and safety of IFN alpha (PDferon) in combination with RIBA on Iranian patients with chronic hepatitis C (CHC).

Methods: 48 naive patients aged 18 years or more with CHC were enrolled and treated with 3 mega units (MU) IFN α -2b three times a week plus 600-1000 mg RIBA per day for 48 weeks. Follow-up after therapy was 6 months. The efficacy was evident at the end of treatment and at the end of follow-up in terms of sustained normalization of alanine aminotransferase and sustained serum HCV-RNA loss.

Results: The rate of sustained biochemical and virologic response were 68.3% and 78%, respectively. 40 patients (83.3%) had at least one not serious complication and 8 patients (16.7%) didn't have any complication. Any patient didn't have serious complication.

Conclusion: Although we had no control group who used standard IFN, our preliminary finding showed acceptable and promising response rate of PDferon. On the other hand, it seems that adverse events with PDferon are as like as other standard IFNs.

Key Words: Interferon, Ribavirin, Hepatitis C, Treatment.

Introduction:

Chronic hepatitis C infection is now recognized as an important health care problem⁽¹⁾. Approximately 2-3% of the world's population is infected with hepatitis C virus (HCV); HCV is one of the leading causes of liver failure and cancer and is the single most common indication for liver transplantation^(2, 3). In Iran the prevalence of HCV infection is about 0.12% in blood donors⁽⁴⁾, but increasing. It seems that the prevalence of HCV infection is less than 1 percent in general population, but the infection is emerging mostly due to problem of intravenous drug use and needle sharing in the country. HCV infection is the most prevalent cause of chronic hepatitis and cirrhosis in hemophilic⁽⁵⁾ and thalassemic⁽⁶⁾ patients and cases with renal failure⁽⁷⁾ in Iran.

During the last decade, interferon- α (IFN- α) monotherapy was established as antiviral treatment of choice for treatment of naive patients with chronic hepatitis C (CHC)⁽⁸⁻¹⁰⁾.

The addition of ribavirin (RIBA) to the standard treatment with IFN- α led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monotherapy to 40-45% in combination therapy⁽¹¹⁻¹²⁾.

The aim of the present study is to assess the therapeutic efficacy and safety of IFN in combination with RIBA on Iranian patients with CHC.

Materials and Methods:

This study is a quasi-experimental according to single group time series

design on patients with chronic hepatitis C referring to Tehran Hepatitis Center during May 2001 to May 2003. All patients received IFN α -2b (PDferon, Pooyesh Darou, Tehran, Iran) at a dose of 3 mega units (MU) given subcutaneously three times a week for 48 weeks with RIBA which was given orally twice or thrice a day to a total dose of 1000 mg (body weight \geq 75 kg, 14 patients), 800 mg (body weight $<$ 75 kg, 32 patients) or 600 mg (2 patients) per day. Both drugs were started and stopped at the same time.

Naive patients 18 years or older, with compensated chronic HCV infection (43 patients) or cirrhosis (5 patients) were eligible for the study. Eligible patients were positive for serum HCV-RNA by RT-PCR (reverse transcriptase polymerase chain reaction), liver biopsy sample taken within a year of entry into the study, had histopathological confirmation of chronic hepatitis and abnormal serum aminotransferase concentration for at least 6 months before start of protocol or normal enzymes while Knodell score is exceeding or equal 4 and fibrosis stage is more than 2.

Entry hemoglobin values had to be at least 120 g/L for women and 130 g/L or more for men. Patients with evidence of decompensated liver disease, HIV-1 or hepatitis-B coinfection, previous organ transplantation, pre-existing psychiatric conditions, seizure disorders, cardiovascular disease, hemoglobinopathies, hemophilia, poorly controlled diabetes, or autoimmune-type disease were not included in the study. All patients were assessed in an outpatient

setting for safety, tolerance, and efficacy at the end of weeks 12, 24, 36, 48 and week 24 after the end of treatment. Biochemical and hematological testing was done by a central commercial laboratory. Serum HCV-RNA was measured qualitatively (Amplicore II, Roche) before treatment and at weeks 12, 48 and week 24 after the end of treatment. Hepatic inflammation and fibrosis were assessed by the Knodell histologic activity index (HAI)⁽¹³⁾.

The estimated sample size of 48 patients was based on a type I error rate of $\alpha=0.05$, with an assumption of treatment benefit being 50% of sustained response rate, the accuracy around this rate equal to 0.15% of standard deviation of this response, using the ratio estimation formula and loss rate equal to 10%.

A serum sample was taken and HBV, HCV, and HIV seromarkers were checked for every subject. For detection of HBV infection, HBV surface antigen (HBsAg) was determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Hepanostika HBsAg Uni-Form II microelisa system, Organon Teknika, Holland). For HCV infection, anti-HCV antibody (anti-HCV Ab) was detected using a third-generation ELISA kit (ETI HCV K-3, DiaSorin, Spain). Complementary test was done with the recombinant immunoblot assay (RIBA-3 Chiron, New Jersey, USA) for positive results of anti-HCV Ab. Patients with both ELISA and RIBA positive reports were considered to be infected with HCV. The serum samples were tested for anti-HIV antibody using ELISA kits (Genscreen HIV, Bio Rad, France).

Indices such as mean, standard error (SE) & percent, tests such as t-test and chi-square (Pearson and McNemar), correlation coefficients such as phi, odds ratio and its 95% confidence interval and repeated measurement method were used in analysis by SPSS version 11.0 software (SPSS Inc. Chicago, Illinois, USA). Correlations with P value < .05 were considered statistically significant. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

Results:

A. Patients characteristics: In the present study 48 patients with chronic hepatitis C were enrolled. Five patients were lost to follow-up due to non hepatic problems in 2 persons, and not having the compliance of drugs in three. Characteristics of other 43 patients are mentioned in table 1.

B. Efficacy

B.1. Virologic response

Serum HCV-RNA level became undetectable in 38 (80.9%) patients at week 12 (EVR: early virologic response). It was 38 (86.4%) at week 48 (ETR: end of treatment virologic response) and 32 (78%) after the end of 24 weeks follow-up (SVR: sustained virologic response). The status of HCV-RNA level was not determined in 1, 4 and 7 cases at week 12, 48 and 72, respectively.

Table 1- Baseline characteristics of the patients

Patients' details	
Sex (% male)	41(85.4%)
Age (years, mean (SE))	39.8(1.7)
Body weight (kg, mean (SE))	74(2)
Source	
Transfusion	30(62.2%)
Intravenous drug abuse	5(10.5%)
Hejamat ^a	5(10.5%)
Extramarital sexual contact	3(6.3%)
Sporadic, other or unknown	5(10.5%)
Biochemistry	
AST ^b (U/I, mean (SE))	76(5)
ALT ^b (U/I, mean (SE))	109(10.4)
Histology ^c	
Grading (mean (SE))	5.9(0.7)
Staging (mean (SE))	2.5(0.3)
Cirrhosis (No.(%))	5(11.1)

a: A procedure in Iranian traditional medicine done by making shallow cuts on the trunk (upper back) and producing a suction effect that results in drawing blood from cuts (less than 100 cc). It is usually done by a non-physician, using non-standard instruments (done for healing or cure purposes).

b: ALT: alanine aminotransferase; AST: aspartate aminotransferase

c: Classification according to modified knodell score

There was a significant correlation between EVR and ETR ($P < 0.001$, $r = 0.823$). In other words, all 36 patients with negative HCV RNA at 12th week (with EVR) had an ETR (negative HCV RNA at the end of treatment), as well. On the contrary, 2 patients from the 7 cases without EVR had an ETR and SVR as well. There wasn't any significant correlation between EVR and SVR. On the other hand, ETR can predict SVR significantly that is negative HCV RNA at the end of treatment causes 24 fold the probability of SVR [$P = 0.008$, $OR = 24.8(2.28-269.63)$].

EVR, ETR, and SVR were observed in 4, 4, and 3 cases of five cirrhotic patients.

B.2. Biochemical response

Biochemical response, during and after treatment is shown in table 2. Mean AST and ALT decreased during treatment, but had a slow rising at the end of follow-up in comparison with the end of treatment. This alteration was significant ($P < 0.001$). Mean AST was significantly higher in cases with positive HCV RNA at 12th week ($P = 0.024$). Although, ALT had higher level in cases without virologic response, but this did not reach statistical significance (Table 3).

Table 2- Biochemical response in different visits

Treatment week	12	24	36	48	End of follow up	Sig.
Liver enzyme						
AST*	40(83.3%)	39(81.3%)	36(85.7%)	37(82.2%)	30(73.2%)	<0.001
ALT*	37(77.1%)	39(81.3%)	34(81%)	38(84.4%)	28(68.3%)	<0.001

*: values are number and the percent of people with normal enzyme (AST≤40U/L, ALT≤45U/L)

Table 3 – Comparison of mean ALT and AST in patients with and without sustained virologic response at 12th week

	Without SVR	With SVR	Sig.
Mean ALT	63±19.2	31.9±3.3	0.147
Mean AST	62.3±13.6	33.1±2.8	0.024

There were 9 patients without sustained virologic response. Three of them had normal ALT (P=0.018). Thirty-five cases (92.1%) from the patients with sustained virologic response had normal ALT (P=0.003). On the other hand, 25 cases (78.1%) from the patients with sustained virologic response had normal ALT (P=0.018). Biochemical and virologic response were closely linked. Thus 78.1% of patients with a sustained virologic response had also a sustained biochemical response (P=0.018).

C. Adverse events and dose reduction:

White blood cell and hemoglobin had decreasing amount until 9th month and then increased till 6 months after the end of treatment (P<0.001). Platelet, neutrophil, PT and weight had a similar pattern, but it was not significant. Anemia (hemoglobin equal or less than 10 g/dl) in 3 patients, dose reduction of RIBA in one non-cirrhotic patient and cease the treatment due to not having the

compliance of drugs in three non-cirrhotic patients were adverse effects of this regimen on these patients. After the beginning of the therapy, thrombocytopenia (platelet less than 150000 per milliliter) was observed in 29.2% of the patients at the 12th week and reached to 45.2% at the 36th week. Then, it decreased till 17.9% at the 24 weeks after the end of treatment. These were 2.4%, 15.4%, and 3.1% regarding neutropenia (neutrophil less than 1500 per milliliter), respectively.

Reticulocyte (P=0.012), total bilirubine (P=0.018) and lactate dehydrogenase (P=0.01) increased until 3rd month after the beginning of treatment. Then, they had a continuous decrease until 6 months after the end of treatment.

Hypothyroidism developed in three patients and required hormone replacement without need for IFN dose reduction. Other complications consists of depression in three cases, and upper limb purpura, vitiligo, and alopecia each one in 1 case. In fact, 40 patients (83.3%) had at least one not serious complication and 8 patients

(16.7%) didn't have any complication. Any patient didn't have serious complication. There was not any death.

Discussion:

Because of the worldwide prevalence of HCV and the mortality associated with cirrhosis, treatment of HCV infection is an important issue. The number of patients with cirrhosis was small (10.4% of patients in this study), but it seems that this group will benefit from 48 weeks of treatment because these patients have extensive fibrosis, are mostly older than 40 years, and are often men⁽¹⁴⁾.

AST and ALT had a continuous decrease until the 36th week and a slow rising until 24 weeks after the end of treatment; although, it didn't reach to its primary level. Likewise, WBC, hemoglobin, platelet and weight had a similar pattern. What happens during the first 36 weeks? Maybe the efficacy of this combination therapy is temporary. Fortunately, it seems that complications are not constant, too. In other words, there is a probable resistance to the efficacy and complications of this therapy after 36 weeks. Maybe it constrains us to change or add other drugs to the present drugs of choice for treatment of patients with chronic HCV in future.

In our study 2 patients from the 7 cases without EVR had an ETR and SVR as well. Consequently, late clearance of HCV RNA from serum during combination therapy was also associated with a sustained response. This phenomenon is uncommon in patients who are treated with IFN alone, which suggests that stopping therapy at week 12 because of persistent viremia, as

previously suggested⁽¹⁵⁻¹⁷⁾ may not be appropriate in the case of therapy with IFN and RIBA.

This relatively high SVR should induce a parallel decrease in the rate of complications. However, this hypothesis must be confirmed by long-term follow-up of the sustained responders to establish the durability of the virologic response and reduction in the development of cirrhosis. Previous trials have already shown that sustained responders are less likely to develop fibrosis-stage cirrhosis⁽¹⁸⁻²⁰⁾.

Discontinuation of therapy was 10.4% for all related and non-related causes that is, equal or less than other similar studies⁽²¹⁻²²⁾. Likewise, no serious adverse effects were seen in this study which meta-analysis studies are in agreement as well⁽²¹⁻²²⁾.

The safety profile in these patients reflects the known side effects of each drug given as monotherapy and is consistent with that reported for patients in relapse⁽²³⁾.

Review of the studies about IFN-RIBA combination therapy for chronic hepatitis C before 1996 suggests that combination therapy results in a two- to threefold greater efficacy than IFN monotherapy, whereas side effects are similar to IFN monotherapy, with the exception of RIBA-induced anemia. The later study showed that the sustained response rate is 46% for naive patients⁽²²⁾.

A meta-analysis from European centers believes that in view of its acceptable toxicity profile, IFN-RIBA combination therapy is a candidate for the new standard therapy for chronic hepatitis C⁽²¹⁾. Another meta-analysis believes that IFN-RIBA combination therapy appears to enhance the efficacy 2-3 fold without increasing

toxicity in comparison with IFN monotherapy⁽²⁴⁾.

In the present study sustained biochemical and virologic response were 68.3% and 78%, respectively. The differences between the results of this study with others may be explained by different populations with respect to genotype, numbers of previous antiviral treatments, and condition of the immune system. Type, dose and duration of IFN appeared to be less important⁽²⁵⁾. Iron load is high in 40-50% of patients with CHC. Iron in the liver, particularly which found in vascular endothelial cells of portal tracts, has been associated with decreased responsiveness to alpha interferon therapy⁽²⁶⁻²⁸⁾. According to liver biopsy, only two patients had hemosiderosis in this study which can be an alternative cause of the acceptable sustained response.

In conclusion, although we had no control group who used standard IFN, our preliminary finding showed acceptable and promising response rate of PDferon. On the other hand, it seems that adverse events

with PDferon are as like as other standard IFNs, although for scientific judgment a control group is necessary. At present, combination therapy with IFN plus RIBA is an acceptable choice in treatment of patients with CHC. Long term follow-up will show the relation between SVR and histological improvement in responder patients.

With the use of combination therapies of increasing efficacy, the number of patients with chronic hepatitis C who relapse after IFN monotherapy is rapidly diminishing; the remaining patients should be retreated with the newest most cost-effective therapeutic protocol.

References:

1. National Institutes of Health consensus Development conference Panel Statement: management of hepatitis C. *Hepatology* 1997;26:suppl 1:2S-10S
2. National Centers for Disease Control and prevention: hepatitis C fact sheet, <http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm>
3. Rosen HR, Martin P. viral hepatitis in liver transplant recipient. *Infect Dis Clin North Am* 2000; 3: 761-784
4. Alavian SM, Gholami B, Masarrat S, Hepatitis C risk factors in Iranian volunteer blood donors, a case control study. *J Gastroenterol Hepatol* 2002; 17: 1092-7
5. Alavian SM, Ardesliri A, Hajarizadeh B, Seroprevalence of anti-HCV Ab among Iranian hemophilia patients. *Transfusion Today* 2001; 49: 4-5
6. Alavian SM, Kafaee J, Yektaparast B, Hajarizadeh B, Doroudi T, The efficacy of blood donor screening in reducing the incidence of hepatitis C virus infection among thalassemic patients in Iran. *Transfusion Today* 2002;53:3-4
7. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S: Prevalence of hepatitis C virus infection and related risk factors among Iranian hemodialysis patients. *Nephrology* 2003;8:256-60
8. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. *Hepatology* 1996;24(4):778-89

9. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. *Hepatology* 1997;26(3 Suppl 1):83S-88S
10. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. *J Viral Hepat* 2001;8(1):48-62
11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998;339(21):1485-92
12. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998;352(9138):1426-32
13. Ishak K, Baptista A, Bianchi L, Cella F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995; 22: 696-9
14. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349(9055):825-32
15. National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C. *Hepatology* 1997;26:Suppl 1:2S-10S
16. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. *Hepatology* 1997;26(6):1640-5
17. McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? *J Hepatol* 1998;29(3):362-8
18. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. *N Engl J Med* 1995;332(22):1457-62
19. Lindsay KL. Therapy of hepatitis C: overview. *Hepatology* 1997;26(3 Suppl 1):71S-77S
20. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. *J Hepatol* 1997;26(6):1187-99
21. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. *J Hepatol* 1997;26(5):961-6
22. Schalm SW, Brouwer JT, Chemello L, Alberti A, Bellobuono A, Ideo G, et al. Interferon-ribavirin combination therapy for chronic hepatitis C. *Dig Dis Sci* 1996;41(12 Suppl):131S-134S
23. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med* 1998;339(21):1493-9
24. Schalm SW, Brouwer JT. Antiviral therapy of hepatitis C. *Scand J Gastroenterol Suppl* 1997;223:46-9
25. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. *J Hepatol* 2003;39(4):606-13
26. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. *Hepatology* 1997; 25: 759-68
27. Bonkovsky HL. Therapy of hepatitis C. Other options. *Hepatology* 1997; 26:(suppl.1): 143S-151S
28. Girelli CM, Mirata C, Iesinigo E, Casiraghi A. Iron overload and response to α -interferon in chronic hepatitis C. *Am J Gastroenterol* 1995; 90: 170-1